First steps towards new therapy for diseases caused by defective anion transport

November 6, 2015, University of Bristol
The top of the image shows the crystal structure in the absence and presence of a bound chloride ion. Below is the proposed mechanism by which the anionophore works. In this case, chloride ions on one side of the cell membrane are exchanged for iodide ions as the anionophore shuttles anions across the cell membrane.

Research by a team at the University of Bristol has taken the first steps towards new treatments for inherited diseases such as cystic fibrosis; one form of Bartter's syndrome (severe salt loss from the kidney); and two forms of myotonia (muscle stiffness), which are linked to defective movement of anions, such as chloride, across cell membranes.

The research, published this week in Nature Chemistry, was led by Professor Tony Davis from the School of Chemistry, and Dr David Sheppard from the School of Physiology and Pharmacology, and was supported by a grant from the Engineering and Physical Sciences Research Council.

Professor Davis said: "The common feature of all these disorders is that they are caused by the loss of channels – gated pathways – which allow chloride ions to stream across cell membranes.

"Drug-like molecules that transport cations across cell membranes have been known about for a long time. Some were discovered as antibiotics, while others are used routinely as tools for biomedical research. By contrast, drug-like molecules that transport anions across cell membranes are almost unknown in nature, and attempts to make them in the laboratory have previously met with limited success."

To develop artificial anion transporters (termed anionophores), Professor Davis and his colleagues synthesized molecules with two distinct parts. One part is designed to bind lipids, the major component of cell membranes. The other is designed to form a cage-like structure to hold a and protect it from lipids. These anionophores work by binding a chloride ion on one side of the cell membrane, shielding the ion from lipids as it is shuttled across the , and then releasing it on the other side.

Dr Sheppard said: "For many inherited diseases that affect anion transport across cell membranes, therapies that treat the root cause of disease are unavailable. For example, the majority of the 10,000 or so individuals living with cystic fibrosis in the UK today use treatments such as chest physiotherapy and antibiotics, which target disease symptoms not the underlying gene defect. For a small number of individuals living with cystic fibrosis, new therapies are now available that target their particular gene defect. If they can be developed into effective medicines, anionophores could be used to treat all individuals living with , irrespective of their particular gene defect."

In previous work, Professor Davis's group had tested anionophores using artificial lipid membranes. In the present study, Dr Hongyu Li working with Dr Sheppard tested 15 anionophores on individual cells and epithelia – the sheets of cells that line ducts and tubes. By monitoring chloride transport in real time through changes in cell fluorescence or electrical activity, Dr Li identified one compound with special promise.

This compound, a bis-(p-nitrophenyl)ureidodecalin derivative, has several important properties. First, it was deliverable to cell membranes. Second, it exhibited robust activity as an anion transporter approaching levels achieved by natural anion transport pathways. Third, its activity was long lasting, transporting chloride for about two hours following a ten-minute treatment period. Fourth, it showed no evidence of toxicity when tested on three different types of cells. Finally, the chemical properties of the bis-(p-nitrophenyl)ureidodecalin derivative approach those of drug-like chemicals.

Explore further: Synthetic molecule makes cancer self-destruct

More information: Hongyu Li et al. Efficient, non-toxic anion transport by synthetic carriers in cells and epithelia, Nature Chemistry (2015). DOI: 10.1038/nchem.2384

Related Stories

Synthetic molecule makes cancer self-destruct

August 11, 2014

Researchers from The University of Texas at Austin and five other institutions have created a molecule that can cause cancer cells to self-destruct by ferrying sodium and chloride ions into the cancer cells.

Tackling the root cause of cystic fibrosis

August 26, 2015

Treatments for cystic fibrosis (CF) have added years to the lives of thousands of Americans. But they can be difficult to administer, and most don't fix the underlying cause. Scientists have now found that a small molecule, ...

An 'unconventional' path to correcting cystic fibrosis

September 1, 2011

Researchers have identified an unconventional path that may correct the defect underlying cystic fibrosis, according to a report in the September 2nd issue of the journal Cell. This new treatment dramatically extends the ...

Lipids support protein machinery

November 5, 2015

In the membranes of mitochondria, the power stations of the cell, are many different embedded proteins. These proteins perform key functions for the mitochondria. A team led by the biochemist Dr. Thomas Becker from the University ...

Recommended for you

First microarrayed 3-D neuronal culture platform developed

November 14, 2018

Neuronal development is often regulated by the graded distribution of guidance molecules, which can either attract or repel the neuronal migration or neurite projection when presented in a format of concentration gradients, ...

Synthetic molecule invades double-stranded DNA

November 12, 2018

Carnegie Mellon University researchers have developed a synthetic molecule that can recognize and bind to double-stranded DNA or RNA under normal physiological conditions. The molecule could provide a new platform for developing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.